Cyclerion: Positive Topline Clinical Data for CY6463 in mitochondrial dysfunction

 Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity

CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontinuation due to adverse events (AEs); oral, once-daily administration provided expected CNS exposure

Data support further development of CY6463 in CNS diseases with mitochondrial dysfunction

https://www.biospace.com/article/releases/cyclerion-therapeutics-announces-positive-topline-clinical-data-for-cy6463-in-melas-patients-at-umdf-mitochondrial-medicine-2022-symposium/